MedTrace Logo

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

NCT00168714 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 329

Last updated 2014-06-09

No results posted yet for this study

Summary

The primary objectives of the study were to prospectively record and analyze birth defects and spontaneous fetal losses in women with multiple sclerosis (MS) exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy, where the outcome of the pregnancy was unknown prospectively and to prospectively record and analyze pregnancy outcomes in an exploratory fashion of women with MS who stopped therapy, but who may have been exposed to Avonex with approximately 1 week of conception or during the first trimester of pregnancy.

Conditions

Interventions

DRUG

BG9418 (interferon beta-1a)

Exposure to Avonex during pregnancy

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168714 on ClinicalTrials.gov